Granulocytopenic Cancer Patients
|
|
- Rosaline Linda Flynn
- 6 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1986, P /86/ $02.00/0 Copyright 1986, Americn Society for Microbiology Vol. 30, No. 1 Rndomized Comprison between Two Ceftzidime-Contining Regimens nd Cephlothin-Gentmicin-Crbenicillin in Febrile Grnulocytopenic Cncer Ptients BARNETT S. KRAMER,t* REUBEN RAMPHAL, AND KENNETH H. RAND Divisions of Medicl Oncology nd Infectious Diseses, University of Florid College of Medicine, Ginesville, Florid Received 12 September 1985/Accepted 17 April 1986 Becuse the results of our published tril [R. Rmphl, B. S. Krmer, K. H. Rnd, R. S. Weiner, nd J. W. Shnds, Jr., J. Antimicrob. Chemother. 12(Suppl. A):81-88, 1983] of ceftzidime versus cephlothin, gentmicin, nd crbenicillin (KGC) reveled prepondernce of grm-positive superinfections, including those cused by clostridi, in ptients treted with ceftzidime, we dded vncomycin to the ceftzidime regimen t study entry 49 nd continued with 2:1 rndomized comprison of ceftzidime-vncomycin (CV) versus KGC. Criteri for study entry were fever (temperture,.38.50c on one occsion or -38C on two occsions 6 h prt) nd grnulocytopeni (<500/mm3 or filing count nticipted to be <500/mm3). Ninety-five entries (79 ptients) were evluble. The numbers of initil clinicl responses for ceftzidime-, KGC-, nd CV-treted ptients were 9 of 21 (43%), 21 of 37 (57%), nd 21 of 37 (57%), respectively; differences were not significnt. The deth rte ws lower with CV (2 of 37 ptients) thn with KGC (10 of 37 ptients) (P < 0.05 by two-tiled nlysis) or with ceftzidime lone (7 of 21 ptients) (P < 0.025). Deth from presumed infections occurred in 9 of 37 KGC-treted ptients versus 1 of 37 CV-treted ptients (P < 0.025). Superinfections occurred in five ceftzidime-treted ptients (24%) versus 7 KGC-treted ptients (19%) but not in CV-treted ptients (CV versus KGC, P < 0.05; CV versus ceftzidime, P < 0.01). CV ppers to be superior to KGC or ceftzidime lone in the mngement of febrile grnulocytopenic cncer ptients. The immedite institution of n empiric brod-spectrum ntimicrobil regimen in febrile cncer ptients with cytotoxic therpy-induced grnulocytopeni hs become ccepted prctice over the lst decde (10, 11). Nevertheless, the optiml ntibiotic regimen hs not been defined, nd the use of vriety of complex two- nd three-drug regimens is commonplce (1, 3-5, 7, 8, 13-15). Some of the three-drug regimes involve up to 13 drug dministrtions per dy, compounding costs nd the potentil for mediction errors nd sometimes requiring delys to llow for the dministrtion of other medictions or blood products. The idel empiric regimen would therefore be single ntibiotic with efficcy t lest equl to tht of more complex regimens nd with low incidence of superinfections nd toxicity, mitigting the need for subsequent dditions of drugs nd redjustments. With these considertions in mind, we initited rndomized comprison of ceftzidime versus cephlothin, gentmicin, nd crbenicillin (KGC) in the initil empiric mngement of febrile grnulocytopenic cncer ptients. Ceftzidime hs excellent ctivity ginst grm-negtive bcilli, the most frequent serious pthogens in grnulocytopenic ptients. It hs modest ctivity ginst grm-positive orgnisms. There hd been t tht time no significnt reports of in vitro development of resistnce or of problem with serious superinfections cliniclly. An nlysis of our tril fter the first 48 study entries reveled comprble initil response rtes between the two tretment progrms; however, s previously reported, there ws n lrming super- * Corresponding uthor. t Present ddress: Ntionl Cncer Institute, NCI-Nvy Medicl Oncology Brnch, Nvl Hospitl, Bethesd, MD infection rte with grm-positive orgnisms in the ceftzidime-treted ptients (9). Becuse of this problem, improved grm-positive coverge ws felt necessry. Idelly, the dditionl drug should not hve significnt effects on gut flor. Vncomycin ws therefore chosen becuse of its excellent grm-positive coverge, including its effectiveness ginst Stphylococcus epidermidis, which hs been emerging in some centers s mjor pthogen, nd becuse it hs little or no biliry excretion (2). A rndomized comprison of ceftzidime plus vncomycin (CV) versus KGC with 2:1 imblnce in fvor of CV ws then begun. We now report the results of the entire study (101 study entries). MATERIALS AND METHODS Ptient entry nd mngement. Study entry criteri were s follows: (i) underlying neoplstic disese; (ii).18 yers old; (iii) grnulocytopeni, s defined by n bsolute neutrophil-plus-bnd count of <500/mm3 or <1,000/mm3 nd flling rpidly; (iv) fever, s defined by n orl temperture of.380c on two occsions 6 h prt or.38.50c on one occsion not ssocited with blood product trnsfusions. Ptients were excluded if they hd received ntibiotics in the preceding 96 h or hd known llergy to penicillin or to ny of the study drugs. All ptients gve written informed consent. Since grnulocytopeni could be nticipted in mny ptients, informed consent ws obtined prior to the onset of fever whenever possible. Neither the ptient nor the person obtining informed consent ws wre of the tretment ssignment t the time consent ws obtined. The initil evlution t study included the following: (i) two blood cultures; (ii) cultures of ny site cliniclly sus-
2 VOL. 30, 1986 EMPIRIC THERAPY FOR GRANULOCYTOPENIA AND FEVER 65 TABLE 1. Unevluble ptients AntibioticUnderlyingNo. of grnulocytes/ Initil infection Out- Superinfection Reson for exclusion regimen disese mm3 come Ceftzidime Lymphom 0 E. coli Died None Moribund t study entry; KCG dded 5 h lter Ceftzidime Leukemi 0 P. eruginos Lived C. tertium nd S. Tobrmycin dded on dy epidermidis 2 Ceftzidime Leukemi 1,188 None Lived None Not grnulocytopenic KGC Lymphom 1,044 None Lived None Not grnulocytopenic C/V Leukemi 500 None Died Pulmonry Switched to KCG on dy 3 spergillosis fter responding on dy 1 to CV-hd whels felt 2 to vncomycin C/V Leukemi 42 None Lived None Switched to KGC fter itching subsequent to first CV dose Added becuse of n inccurte lbortory report of susceptibility. The ptient ws febrile nd hd sterile blood culture t this time. pected of being infected; (iii) chest roentgenogrm; (iv) urinlysis; nd (v) serum electrolyte, blood ure nitrogen, cretinine, nd liver function tests. The first 48 study entries were rndomly ssigned to receive either ceftzidime lone (2 g intrvenously every 8 h) or cephlothin (3 g intrvenously every 6 h), gentmicin (1.5 mg/kg intrvenously every 8 h), nd crbenicillin (500 mg/kg per dy) (mximum, 36 g/dy) (KGC) in six dily divided doses. From study entry 49 through 101, there ws 2:1 rndomiztion to receive either ceftzidime s described bove plus vncomycin (500 mg intrvenously every 6 h) or KGC. The ntibiotics in ny individul ptient were chnged only if cultures reveled orgnisms resistnt to the ssigned regimen. The ntibiotics were continued until the grnulocyte count ws >500/mm3 on two successive dys nd the temperture ws <38 C for t lest 24 h. Amphotericin B ws dded empiriclly (0.5 to 0.7 mg/kg per dy) on dy 8 if the ptient ws febrile nd grnulocytopenic without documented source of fever. It ws dded fter dy 8 if febrile, persistently grnulocytopenic ptients subsequently redeveloped fever. Since the empiric ddition of mphotericin B cme no erlier thn dy 8, it did not in ny wy ffect the determintion of the initil clinicl response. Serum gentmicin levels were monitored, nd doses were djusted to chieve pek serum level of 4 to 8 mg/liter nd trough serum level of <2 mg/liter. Chest roentgenogrms were obtined weekly fter study entry or more frequently if pulmonry symptoms or signs evolved. Two sets of blood cultures were obtined once dily if ptients continued to be febrile. Bcteril isoltes were tested for susceptibility to ceftzidime by microtiter nd tube broth dilutions. Definitions of response ctegories. A fvorble clinicl response ws defined s ptient becoming febrile (temperture, <380C) within 96 h of the initition of ntibiotics nd remining febrile for t lest 48 h. A fvorble bcteriologicl response ws defined s the termintion of documented bcteremi on repet cultures regrdless of the febrile response. There were no instnces of microbiologiclly documented soft tissue infections which were not ccompnied by bcteremi. Since cultures of cellulitis re insensitive in our experience, we relied on blood culture results for the determintion of bcteriologicl response. A new fever ws one which occurred fter fvorble clinicl response. A superinfection ws considered to be documented infection by new orgnism while the ptient ws receiving therpy. Deths were ctegorized s being due to initil infections (whether cliniclly or microbiologiclly defined), superinfections, or other cuses (e.g., cerebrl hemorrhge, myocrdil infrction). Sttisticl nlysis. All comprisons of outcome by tretment group were done by two-tiled chi-squre nlysis. All comprisons of mens were done by the student t tests (nd by the Wilcoxon rnk sum test for ptient ge comprisons). Sttisticl significnce did not chnge whether ll ptients entered were nlyzed or the six unevluble ptients were excluded. There ws no sttisticl difference between the 23 entries ssigned to KGC in the first phse, of the study nd the 14 entries ssigned to KGC in the second phse of the study with regrd to initil grnulocyte count, durtion of grnulocytopeni, clinicl response, or deth. For n nlysis of the intensity of chemotherpy of the three tretments, one of us, medicl oncologist (B.S.K.), mde the ssignments retrospectively. In generl, the designtion of intensive therpy ws reserved for ptients undergoing induction or consolidtion therpy for cute leukemi nd occsionl ptients with solid tumors who underwent high-dose therpy, which usully results in grnulocytopeni for more thn 2 weeks. RESULTS There were totl of 101 study entries (85 ptients) from Jnury 1982 through September Ninety-five entries (79 ptients) were considered evluble. Three ptients in the ceftzidime group were considered unevluble: one ws ineligible becuse grnulocytopeni ws not chieved; nother ws moribund t study entry, nd the treting physicin decided to dd KGC 5 h fter study entry; nd tobrmycin ws dded on dy 2 of the study in the third, despite good clinicl nd bcteriologicl response, becuse of n erroneous susceptibility report. One KGC entry ws ineligi-
3 66 KRAMER ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 2. Ptient chrcteristics (evluble ptients) Prmeter Ceftzidime KGC CV (n = 21) (n = 37) (n = 37) No. of mles/femles 10/11 15/22 19/18 Medin ge (rnge) 43 (21-88) 56 (20-77) 35 (18-66) Men ge Dignosisb (no. of ptients) Acute leukemi Solid tumor Intensive chemotherpy (no of ptients) Medin grnulocytes/mm3 t 34 (0-435) 6 (0-888) 20 (0-1,000) study entry (rnge) Men grnulocytes/mm3 82 t t t 324 t study entry t SD No. of dys grnulocytopenic Medin (rnge) 12 (2-38) 10 (1-38) 15 (2-39) Men No differences between groups re sttisticlly significnt, except where noted. b CV versus KGC, P < 0.05; others, P not significnt. ble becuse grnulocytopeni did not occur. Two CV entries were unevluble: both were switched to KGC fter the ptients hd cutneous rections to the vncomycin infusion erly in the course of therpy. These six unevluble ptients nd outcomes re listed in Tble 1. The chrcteristics of the remining 95 entries re listed in Tble 2. There were no sttisticlly significnt differences mong the three tretments with regrd to sex, ge, intensity of chemotherpy, initil grnulocyte count, or durtion of grnulocytopeni t <500/mm3. It should be noted tht the medin durtion of grnulocytopeni in ech group ws reltively long, 12, 10, nd 15 dys. There ws n imblnce in the distribution of the tretments by dignosis, since the CV group hd significntly higher proportion of cute TABLE 3. Therpeutic responses Prmeter Ceftzi- KC dime (n 7) (n = 21) n=3) (n=-37) n=37 No. (%) of clinicl responses 9 (43) 21 (57) 21 (57) No. (%) with bcteriologicl 4/5 (80) 4/5 (80) 4/4 (100) cure of bcteremis Durtion of fever in responders (dys) Medin (rnge) 1 (1-4) 2 (1-4) 2 (1-4) Men No. (%) of ptients with new 7 (78) 12 (57) 15 (71) fevers during therpy Superinfections No. (%) of ptientsb 5 (24) 7 (19)c 0 No. of different orgnisms No. of dethsd cused by: Infections Superinfections Other No. of ptients receiving 8/9 11/14 20/23 mphotericin B/no. of ptients eligible Differences not significnt. b CV versus ceftzidime, P < 0.01; CV versus KGC, P < 0.05; ceftzidime versus KGC, P not significnt. c One KGC ptient developed new pulmonry infiltrte with recurrence of fever fter n initil clinicl response, but there ws no microbiologicl documenttion of the etiology. d CV versus ceftzidime, P < 0.025; CV versus KGC, P < 0.05; ceftzidime versus KGC, P not significnt. leukemi ptients thn did the KGC group: 33 of 37 versus 25 of 37 (P < 0.05). There were no significnt differences between the KGC ptients in the first versus the second prts of the study with regrd to sex, ge, dignosis, proportion undergoing intensive chemotherpy, men nd medin grnulocyte counts t study entry, durtion of grnulocytopeni, or outcome. Therpeutic responses nd outcomes re shown in Tble 3 for the three groups. Although the initil clinicl response rte in the ceftzidime group ws 43%, compred with 57% in ech of the other two groups, this difference ws not sttisticlly significnt. Similrly, the bcteriologicl response rtes mong the three groups were nerly identicl. The initil orgnisms responsible for documented bcteremis nd their outcomes re listed in Tble 4. The sole bcteriologicl filure in the ceftzidime group ws in ptient with overwhelming Escherichi coli sepsis in the setting of mssive gstrointestinl ulcertion resulting from high-dose 5-fluorourcil. The sole bcteriologicl filure in the KGC group ws n episode of Pseudomons eruginos sepsis. There were no filures in the CV group. The durtion TABLE 4. Outcome of microbiologiclly documented bcteremis Drug nd no. Orgnism Outof ptients come Ceftzidime 2 E. coli Died 18 P. eruginos Cured 23 C. subterminle Cured 28 E. coli Cured 33 Klebsiell sp. Cured KCG 7 P. eruginos Cured 11 Enterococcus sp. Cured 14 P. eruginos Cured 17 P. eruginos Died 63 P. eruginos Cured CV 53 S. ureus Cured 71 S. ureus Cured 85 S. ureus Cured 99 S. ureus Cured
4 VOL. 30, 1986 EMPIRIC THERAPY FOR GRANULOCYTOPENIA AND FEVER 67 TABLE 5. Outcome of microbiologiclly documented superinfections Drug nd no. Superinfecting orgnism(s) Dy of Outcome of ptients superinfectionoucm Ceftzidime 1 C. septicum 10 Died 3 Enterococcus sp. 14 Died (noninfectious cuse) 18 C. perfringens nd Enterococcus sp. 5 nd 7 Died 45 C. tertium nd Citrobcter sp. 17 nd 17 Died 47 C. septicum nd Enterococcus sp. 11 nd 11 Died KCG 7 E. coli 9 Lived 11 P. eruginos 20 Died 27 Cndid lbicns 19 Died 32 C. lbicns 8 Lived 34 P. cepci 1, B. frgilis, nd P. cepci 2 18, 27, nd 32 Lived 36 P. eruginos 10 Died CV None None of fevers in responding ptients ws quite similr in ech group. The recurrence rtes of fever in the ceftzidime, KGC, nd CV groups were 78, 57, nd 71%, respectively (P not significnt). Sttisticlly significnt differences, however, emerged for the nlysis of deth rte by tretment ssignment (Tble 3). Of 21 ptients treted with ceftzidime, 7 died, compred with 10 of 37 KGC-treted ptients nd only 2 of 37 CVtreted ptients (CV versus ceftzidime, P < 0.025; CV versus KGC, P < 0.05; ceftzidime versus KGC, P not significnt). One deth in ech of the three groups ws considered to hve noninfectious cuse. Deth due to presumed infections occurred in totl of 6 of 21 ceftzidime-treted ptients, 9 of 37 KGC-treted ptients, nd 1 of 37 CV-treted ptients (KGC versus CV, P < 0.025; ceftzidime versus CV, P < 0.05; KGC versus ceftzidime, P not significnt). Of these, there were 4 deths due to documented superinfections in the ceftzidime group, 3 in the KGC group, nd none in the CV group. There were lso significnt differences mong the groups with regrd to documented superinfections. Of 21 ptients who received ceftzidime, 5 (24%) developed superinfections (eight orgnisms), compred with 7 of 37 (19%) ptients who received GKC (eight orgnisms) nd none of 37 ptients who received CV (CV versus ceftzidime, P < 0.01; CV versus KGC, P < 0.05; ceftzidime versus KGC, P not significnt). As previously reported, there ws striking difference in the profiles of superinfecting orgnisms between the ceftzidime nd KGC regimens (Tble 5). Seven of eight superinfections occurring in ptients receiving ceftzidime were cused by grm-positive orgnisms, compred with prepondernce of grm-negtive orgnisms (five of eight superinfections) in those receiving KGC. There were two episodes of cndidemi in the KGC group, one of them ftl. The outcomes of ll microbiologiclly documented superinfections re shown in Tble 5. Autopsies were performed on 5 of the 19 evluble ptients who died. One of the five, who hd been given ceftzidime, ws determined to hve noninfectious cuse of deth from progressive Hodgkin's disese nd crdic tmponde. The remining four hd utopsy-proven infectious cuses of deth, s follows: Clostridium sepsis, Clostridium sepsis with orgnisms in multiple orgns, pulmonry spergillosis, nd overwhelming E. coli sepsis in the setting of bloody dirrhe cused by chemotherpy-induced bowel mucositis. Since potentil bis in nlyzing deths mong the groups would be n imblnce in the frequency of initition of mphotericin B therpy on dy 8 in febrile neutropenic ptients, s stipulted in the study protocol, we took this into ccount. Indeed, some of the primry physicins were reluctnt to dd mphotericin B in febrile neutropenic ptient who ppered to be stble. Of nine ptients who qulified for the ddition of mphotericin B while receiving ceftzidime, eight ctully received it. This compres with 11 of 14 ptients receiving KGC nd 20 of 23 ptients receiving CV. None of these differences pproched sttisticl significnce (Tble 3). No cses of renl filure occurred, nd no deths were ttributed to ny of the ntibiotics used. Rshes or pruritis occurred in one ceftzidime-treted ptient, two KGCtreted ptients nd four CV-treted ptients. Two cses of fluid overlod occurred, both in the KGC group. DISCUSSION A vriety of empiric brod-spectrum ntimicrobil regimens hve been used nd compred in the initil mngement of febrile neutropenic cncer ptients, but none hs demonstrted cler superiority (1, 3-5, 7, 8, 13-15). A possible reson is tht minor chnges in spectrum cnnot be expected to yield mjor differences in response rtes, s long s most of the commonly infecting orgnisms in the ptient popultion re within the spectrum of the regimen chosen. Indeed, the initil clinicl response rtes in our own study were similr in the single, double, nd triple ntibiotic regimens. Admittedly, the, error (chnce of missing reltively smll initil response rte differences) ws lrge. Bsed on two-sided nlysis with n x error (chnce of declring difference between two regimens exists when, in fct, none exists) of 0.05, the chnce of detecting n improvement in the response from 45% with ceftzidime to 65% with KGC ws only bout 40% (I error, 0.6). Likewise, the P error ws lso bout 0.6 in the bility to detect n improvement in the response from 55% with KGC to 75% with CV. Lrge differences in efficcy nd outcome between groups did not emerge until lter in the tretment course of these ptients, t which time there were differences in
5 68 KRAMER ET AL. superinfection nd deth rtes. Hence, regimen which hs the sme initil response rte my ultimtely prove superior to nother if there re fewer superinfections or deths. One might rgue tht it would be dvntgeous to strt with single brod-spectrum ntibiotic such s ceftzidime nd mke djustments in coverge s becomes necessry lter in the tretment course. Indeed, recent preliminry report by Pizzo et l. showed tht ceftzidime my be s effective s KGC in the initil mngement of febrile grnulocytopenic cncer ptients (P. Pizzo, M. Thler, J. Hiemenz, D. Cotton, J. ithorn, J. Commers, J. Gress, D. Mrshll, D. Longo, nd M. Browne, Progrm Abstr. 24th Intersci. Conf. Antimicrob. Chemother., bstr. no. 380, 1984). However, tht report ws for younger popultion (medin ge, 25) thn our own, with shorter durtion of grnulocytopeni (medin, 8.5 dys). Adjustments in ntibcteril coverge were often necessry fter the first 72 h of therpy. Moreover, one cnnot ccurtely predict in ny given episode precisely when superinfection will emerge. In fct, one of our ptients receiving ceftzidime developed superinfection with Clostridium perfringens on dy 5 of therpy. Seril surveillnce cultures re generlly of no benefit in predicting infective orgnisms (6). Our initil hope ws to find single-gent regimen which would mtch the effectiveness of the brod-spectrum coverge of cephlosporin, n minoglycoside, nd n ntipseudomonl penicillin. Becuse of surprisingly high rte of superinfection with grm-positive orgnisms, including nerobes, we felt tht the combintion of ceftzidime nd vncomycin would cover the "holes." After the initition of our study, there ws report of the emergence of resistnt orgnisms in ptients treted with ceftzidime (12). However, these were primrily P. eruginos in ptients with cystic fibrosis. We were subsequently impressed by the complete bsence of documented superinfections with the two-drug combintion. This ppers to trnslte into lower mortlity rte thn for either stndrd KGC tretment or ceftzidime tretmnent. Nevertheless, severl conclusions re probbly wrrnted. (i) Ceftzidime, KGC, nd CV hd comprble initil response rtes when used s initil empiric htimicrobil therpy in dult febrile grnulocytopenic cncer ptients. (ii) Ceftzidime lone ws ssocited with high superinfection rte with grm-positive orgnisms, nd KGC ws ssocited with predominntly grm-negtive superinfections. This stnds in contrst to CV, with which no superinfections were documented. (iii) CV ws ssocited with fewer deths thn ws ceftzidime lone or KGC nd ppers to be the superior regimen in febrile grnulocytopenic cncer ptients. Of course, s newer individul ntibiotics with even broder spectr become vilble, the sitution must be ressessed. ANTIMICROB. AGENTS CHEMOTHER. ACKNOWLEDGMENT This study ws supported by contribution from Glxo, Inc. LITERATURE CITED 1. Brown, A. E Neutropeni, fever, nd infection. Am. J. Med. 76: Cook, F. V., nd W. E. Frrr, Jr Vncomycin revisited. Ann. Intern. Med. 88: DeJongh, C. A., J. C. Wde, S. C. Schimpff, K. A. Newmn, R. S. Finley, P. C. Slvtore, M. R. Moody, H. C. Stndiford, C. L. Fortner, nd P. H. Wiernik Empiric ntibiotic therpy for suspected infection in grnulocytopenic cncer ptients. Am. J. Med. 73: Klstersky, J Therpy of bcteril infections in cncer ptients, p In J. Verhoef, P. K. Peterson, nd P. G. Quie, (ed.), Infections in the immunocompromised host-pthogenesis, prevention, nd therpy. Elsevier Biomedicl Press, Amsterdm. 5. Klstersky, J Tretment of severe infections in ptients with cncer. Arch. Intern. Med. 142: Krmer, B. S., P. A. Pizzo, K. Robichud, F. Witebsky, nd R. Wesley Role of microbiologic surveillnce nd clinicl evlution in the mngement of cncer ptients with fever nd grnulocytopeni. Am. J. Med. 72: Love, L. L., S. C. Schimpff, C. A. Schiffer, nd P. H. Wiernik Improved prognosis for grnulocytopenic ptients with grm negtive bcteremi. Am. J. Med. 68: Pizzo, P. A., K. J. Robechud, F. A. Gili, nd F. A. Witebsky Empiric ntibiotic nd ntifungl therpy for cncer ptients with prolonged fever nd grnulocytopeni. Am. J. Med. 72: Rmphl, R., B. S. Krmer, K. H. Rnd, R. S. Weiner, nd J. W. Shnds, Jr Erly results of comprtive tril of ceftzidime versus cephlothin, crbenicillin, nd gentmicin in the tretment of febrile grnulocytopenic ptients. J. Antimicrob. Chemother. 12(Suppl. A): Schimpff, S. C., nd J. Aisner Empiric ntibiotic therpy. Cncer Tret. Rep. 62: Schimpff, S. C., W. Stterlee, V. M. Young, nd A. Serpick Empiric therpy with crbenicillin nd gentmicin for febrile ptients with cncer nd grnulocytopeni. N. Engl. J. Med. 284: Scully, B. E., nd H. C. Neu Clinicl efficcy of ceftzidime: tretment of serious infection due to multiresistnt Pseudomons nd other grm-negtive bcteri. Arch. Intern. Med. 144: Singer, C., M. H. Kpln, nd D. Armstrong Bcteremi nd fungemi complicting neoplstic disese: study of 364 cses. Am. J. Med. 62: Wde, J. C., S. C. Schimpff, K. A. Newmn, C. L. Fortner, H. C. Stndiford, nd P. H. Wiernik Pipercillin or ticrcillin plus mikcin. Am. J. Med. 71: Winston, D. J., W. G. Ho, L. S. Young, W. L. Hewitt, nd R. P. Gle Pipercillin plus mikcin therpy in febrile grnulocytopenic ptients. Arch. Intern. Med. 142:
Role of Vancomycin as a Component of Oral Nonabsorbable Antibiotics for Microbial Suppression in Leukemic Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mr. 1979, p. 455-460 0066-4804/79/03-0455/06$02.00/0 Vol. 15, No. 3 Role of Vncomycin s Component of Orl Nonbsorbble Antibiotics for Microbil Suppression in Leukemic
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationUsing Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids
Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress
More informationGentamicin, Tobramycin, Netilmicin, or Amikacin and Carbenicillin or Ticarcillin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1979, p. 592-596 66-484/79/4-592/5$2./ Vol. 15, No. 4 Effect of Time nd Concentrtion Upon Interction Between Gentmicin, Tobrmycin, Netilmicin, or Amikcin nd
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationCord Injuries. on admission, and intermittent catheterization. (IC) was carried out until spontaneous voiding occurred.
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1982, P. 856-860 0095-1137/82/110856-05$02.00/0 Copyright 1982, Americn Society for Microbiology Vol. 16, No. 5 Pseudomons eruginos Coloniztion in Ptients with Spinl
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationManagement of infective complications in patients with advanced hematologic malignancies in home care
Leukemi (1997) 11, 1807 1812 1997 Stockton Press All rights reserved 0887-6924/97 $12.00 Mngement of infective complictions in ptients with dvnced hemtologic mlignncies in home cre C Girmeni, ML Moleti,
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationS Seropian 1, R Nadkarni 1, AP Jillella 1, E Salloum 1, B Burtness 1,GLHu 2, D Zelterman 2 and DL Cooper 1. Summary:
Bone Mrrow Trnsplnttion, (1999) 23, 599 605 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Neutropenic infections in 100 ptients with non-hodgkin s lymphom
More informationIn Vitro Activities of Moxalactam and Cefotaxime Against Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 90, p. 937-9 0066-0/0/06-0937/06$0.00/0 Vol. 7, No. 6 In Vitro Activities of nd Aginst Aerobic Grm-Negtive Bcilli J. H. JORGENSEN,* S. A. CRAWFORD, AND G. A.
More informationRecommended Dosage Regimen for AVYCAZ (ceftazidime and avibactam) b. AVYCAZ 1.25 grams (ceftazidime 1 gram and avibactam 0.25 grams) every 8 hours
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use AVYCAZ sfely nd effectively. See full prescribing informtion for AVYCAZ. AVYCAZ (ceftzidime nd vibctm)
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationR Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1
Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationSummary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV)
Summry Effect evlution of the Rehbilittion of Drug-Addicted Offenders Act (SOV) The Rehbilittion of Drug-Addicted Offenders Act (SOV) ws lunched on April first 2001. This lw permitted the compulsory plcement
More informationEffect of Sodium Polyanethol Sulfonate in Blood Cultures
JOURNAL OF CLINICAL MICROBIOLoGY, Feb. 1975, p. 119-123 Copyright 0 1975 Americn Society for Microbiology Vol. 1, No. 2 Printed in U.S.A. Effect of Sodium Polynethol Sulfonte in Blood Cultures JAN ENG
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationInfections with Cephapirin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1974, p. 274-281 Copyright @ 1974 Americn Society for Microbiology Vol. 6, No. 3 Printed in U.S.A. Tretment of Pneumoni nd Other Serious Bcteril Infections
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationFirst-line and Maintenance Treatment with ALIMTA therapy for advanced nonsquamous non-small cell lung cancer (NSCLC)
YOUR LIFE. First-line nd Mintennce Tretment with ALIMTA therpy for dvnced nonsqumous non-smll cell lung cncer (NSCLC) ALIMTA is pproved by the FDA in combintion with cispltin (nother chemotherpy drug)
More informationUrinary Tract Infection in Women
C H A P T E R 1 8 Urinry Trct Infection in Women Toms L. Griebling, MD Associte Professor & Vice Chir of Urology University of Knss Knss City, Knss Contents INTRODUCTION........................................589
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationHospital-acquired infections have a higher mortality
Dignosis nd Tretment of Ventiltor-Associted Infection: Review of the Criticl Illness Stress-Induced Immune Suppression Prevention Tril Dt Dougls F. Willson, MD 1 ; Angel Webster, PhD 2 ; Sbrin Heidemnn,
More informationIncidence, clinical outcome, and risk stratification of ventilator-associated pneumonia a prospective cohort study
IJCCM October-December 2003 Vol 7 Issue 4 Indin J Crit Cre Med October-December 2005 Vol 9 Issue 4 Originl Article Incidence, clinicl outcome, nd risk strtifiction of ventiltor-ssocited pneumoni prospective
More informationDialysis Effluent. lines and catheters, and wound sites. An attempt was made. to discern those factors which might adversely affect the
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1987, p. 2367-2371 0095-1137/87/122367-05$02.00/0 Copyright C 1987, Americn Society for Microbiology Vol. 25, No. 12 Lbortory Indices of Clinicl Peritonitis: Totl
More informationComparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight
Bone Mrrow Trnsplnttion, (1999) 23, 867 873 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of utologous peripherl blood stem cell dosing by idel
More informationEVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1
Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were
More informationDose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification
Hshimoto et l. BMC Phrmcology nd Toxicology (2017) 18:74 DOI 10.1186/s40360-017-0180-3 RESEARCH ARTICLE Open Access Dose-dependent effect of dptomycin on the rtificil prolongtion of prothrombin time in
More informationLevofloxacin in the Treatment of Pneumonia Caused by Streptococcus pneumoniae, Including Multidrug-Resistant Strains
Levofloxcin in the Tretment of Pneumoni Cused by Streptococcus pneumonie, Including Multidrug-Resistnt Strins Review Jnet Peterson, PhD Ortho-McNeil Jnssen Scientific Affirs, LLC; Rritn, New Jersey, USA
More informationTR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:
(2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron
More informationEpidemiology and Clinical Features of Post-Transplant Bloodstream Infection: An Analysis of 222 Consecutive Liver Transplant Recipients
Originl Article http://dx.doi.org/10.3947/ic.2013.45.3.315 Infect Chemother 2013;45(3):315-324 pissn 2093-2340 eissn 2092-6448 Infection & Chemotherpy Epidemiology nd Clinicl Fetures of Post-Trnsplnt Bloodstrem
More informationPharmacokinetics of Single-Dose Oral Ciprofloxacin in Patients Undergoing Chronic Ambulatory Peritoneal Dialysis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1986, p. 152-156 0066-4804/86/070152-05$02.00/0 Copyright 1986, Americn Society for Microbiology Vol. 30, No. 1 Phrmcokinetics of Single-Dose Orl Ciprofloxcin
More informationThe Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes
Originl Article doi: 10.4093/kdj.2010.34.3.166 pissn 1976-9180 eissn 2093-2650 The Effects of Smll Sized Rice Bowl on Crbohydrte Intke nd Dietry Ptterns in Women with Type 2 Dibetes Hee-Jung Ahn 1, *,
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationThe potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens
The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic
More informationUS Food and Drug Administration-Mandated Trials of Long-Acting b -Agonists Safety in Asthma. Samy Suissa, PhD ; and Amnon Ariel, MD, FCCP
CHEST Commentry US Food nd Drug Administrtion-Mndted Trils of Long-Acting b -Agonists Sfety in Asthm Will We Know the Answer? Smy Suiss, PhD ; nd Amnon Ariel, MD, FCCP For 2 decdes, long-cting b -gonists
More informationPotential for Interactions Between Dietary Supplements and Prescription Medications a
CLINICAL RESEARCH STUDY Potentil for Interctions Between Dietry Supplements nd Prescription Medictions Amit Sood, MD, MSc, Rich Sood, MD, b Frncis J. Brinker, ND, Rvneet Mnn, MBBS, c Lur L. Loehrer, Dietlind
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationEFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE
Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationP (RCC) was first done in the late 1930s and reported in
Pulmonry Resection of Metsttic Renl Cell Crcinom Robert J. Cerfolio, MD, Mrk S. Allen, MD, Clude Deschmps, MD, Richrd C. Dly, MD, Steven L. Wllrichs, BS, Victor F. Trstek, MD, nd Peter C. Pirolero, MD
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationSubcutaneous ventricular catheter reservoir and ventriculoperitoneal drain-related infections in preterm infants and young children
ORIGINAL ARTICLE Subcutneous ventriculr ctheter reservoir nd ventriculoperitonel drin-relted infections in preterm infnts nd young children N. Bruinsm 1, E. E. Stobberingh 1, M. J. H. M. Herpers 2, J.
More informationUrinary Tract Infection in Men
C H A P T E R 1 9 Urinry Trct Infection in Men Toms L. Griebling, MD Associte Professor & Vice Chir of Urology University of Knss Knss City, Knss Contents INTRODUCTION........................................623
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2011 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use GEMZAR sfely nd effectively. See full prescribing informtion for GEMZAR. GEMZAR (gemcitbine for injection)
More informationEffect of Preoperative Intravenous Methocarbamol and Intravenous Acetaminophen on Opioid Use After Primary Total Hip and Knee Replacement
Feture Article Effect of Preopertive Intrvenous Methocrbmol nd Intrvenous Acetminophen on Opioid Use After Primry Totl Hip nd Knee Replcement THOMAS D. LOOKE, MD, PHD; CAMERON T. KLUTH, MBA bstrct Between
More informationBENIGN ulceration along the greater curvature of the pars media of the
BENIGN ULCERS OF THE GREATER CURVATURE OF THE STOMACH Report of Two Cses CHARLES H. BROWN, M.D. Deprtment of Gstroenterology nd ANTHONY D. INTRIERE, M.D.* BENIGN ulcertion long the greter curvture of the
More informationInvasive Pneumococcal Disease Quarterly Report July September 2018
Invsive Pneumococcl Disese Qurterly Report July Septemer Introduction Since 17 Octoer 2008, invsive pneumococcl disese (IPD) hs een notifile to the locl Medicl Officer of Helth under the Helth Act 1956.
More informationSingle-Dose Accumulation Pharmacokinetics of Tobramycin and Netilmicin in Normal Volunteers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1987, p. 65-69 66-484/87/465-5$2./ Copyright 1987, Americn Society for Microbiology Vol. 31, No. 4 Single-Dose Accumultion Phrmcokinetics of Tobrmycin nd Netilmicin
More informationRecall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study
Syddnsk Universitet Recll Bis in Childhood Atopic Diseses Among Adults in The Odense Adolescence Cohort Study Mørtz, Chrlotte G; Andersen, Klus Ejner; Bindslev-Jensen, Crsten Published in: Act Dermto-Venereologic
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationAnalysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia
284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,
More informationBacteriology of War Wounds at the Time of Injury
MILITARY MEDICINE, 171, 9:826, 2006 Bcteriology of Wr Wounds t the Time of Injury Gurntor: MAJ Clinton K. Murry, MC USA Contributors: MAJ Clinton K. Murry, MC USA*; MAJ Sturt A. Roop, MC USA ; LTC(P) Dune
More informationOpen Forum Infectious Diseases MAJOR ARTICLE
Open Forum Infectious Diseses MAJOR ARTICLE Epidemiology of Dibetic Foot Infection in the Metro-Detroit Are With Focus on Independent Predictors for Pthogens Resistnt to Recommended Empiric Antimicrobil
More informationThe Prevalence of Bacteremia in Pediatric Patients With Community-Acquired Pneumonia: Guidelines to Reduce the Frequency of Obtaining Blood Cultures
RESEARCH ARTICLE The revlence of Bcteremi in editric tients With Community-Acquired neumoni: Guidelines to Reduce the Frequency of Obtining Blood Cultures bstrct OBJECTIVE: The gol of this study ws to
More informationEvaluation of New Urinary Tract Infection Screening Devices
APPLIED MICROBIOLOGY, Aug. 1973, p. 196-201 Copyright 0 1973 Americn Society for Microbiology Vol. 26, No. 2 Printed in U.S.A. Evlution of New Urinry Trct Infection Screening Devices WILLIAM A. CRAIG,
More informationWeight-Based Dosage Regimen: (2.1) Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) greater or equal to 40 to less than 60 2,400 3,000
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (rvulizumb-cwvz) injection, for intrvenous
More informationNatural History of Left Anterior Descending Coronary Artery Obstruction: Significance of Location of Stenoses in Medically Treated Patients
Clin. Crdiol. 8, 415-422 (1985) 0 Clinicl Crdiology Publishing Co., Inc. Originl Contributions Nturl History of Left Anterior Descending Coronry Artery Obstruction: Significnce of Loction of Stenoses in
More informationRheumatoid-susceptible alleles of HLA-DRB 1 are genetically recessive to non-susceptible alleles in the progression of bone destruction in the wrists
Annls of the Rheumtic Diseses 1994; 53: 587-592 587 Deprtment of Orthopedic Surgery, Knsi Medicl University, Otokoym Hospitl, Kyoto, Jpn Y Tod Y Mori Deprtment of Orthopedic Surgery, Knsi Medicl University,
More informationRadiation therapy (RT) for cancer that involves the thorax
Originl Article Prospective Explortory Anlysis of Crdic Biomrkers nd Electrocrdiogrm Abnormlities in Ptients Receiving Thorcic Rdition Therpy with High-Dose Hert Exposure Dniel R. Gomez, MD,* Syed Wmique
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationTHE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS
THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS John F. Ptience nd Doug Gillis SUMMARY
More informationPredictors of Hospitalization in Male Marine Corps Recruits with Exertional Heat Illness
MILITARY MEDICINE, 169, 3:169, 2004 Predictors of Hospitliztion in Mle Mrine Corps Recruits with Exertionl Het Illness Gurntor: COL John W. Grdner, MC FS USA Contributors: Shilp Hkre, DrPH; COL John W.
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationMecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert:
SWINE (Crbdox) Improves pig performnce in wide rnge of helth nd growing conditions The Advntge Over the yers, medicted feed dditive hs proven to be cost-effective mngement tool for improving pig performnce
More informationDr. Gary E. Vallad, Associate Professor, UF/IFAS, Gulf Coast REC
Dr. Gry E. Vlld, Associte Professor, UF/IFAS, Gulf Cost REC Florid Production: 35,ooo production crege $456 million production vlue Nerly yer-long production Florid Production: 35,ooo production crege
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationChilblains (pernio, perniosis) are cold-induced, painful or itching
Nifedipine vs Plcebo for Tretment of Chronic Chilblins: A Rndomized Controlled Tril Ibo H. Souwer, MD 1 Jcobus H. J. Bor, BSc (Mth) 2 Pul Smits, MD, PhD 3 Antoine L. M. Lgro-Jnssen, MD, PhD 1 1 Deprtment
More informationWSU Tree Fruit Research and Extension Center, Wenatchee (509) ext. 265;
FINAL REPORT WTFRC Project # AH-1-5 WSU Project # 13C-355-3 Project title: PI: Orgniztion: Coopertors: of Sunburn in Apples with RAYNOX Lrry Schrder, Horticulturist WSU Tree Fruit Reserch nd Extension
More informationEstimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain
Rpid communictions Estimting the impct of the influenz pndemic on mortlity in the elderly in Nvrre, Spin J Cstill (jcstilc@nvrr.es) 1, J Etxeberri 1, E Ardnz 1, Y Floristán 1, R López Escudero 1, M Guevr
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationGemmis Injection 38 mg/ml
Gemmis Injection 8 mg/ml Gemcitbine (Gemcitbine HCl) is nucleoside nlogue tht exhibits nti-tumor ctivity. The empiricl formul for Gemcitbine HCl is C 9H 11F 2N O.HCl. It hs moleculr weight of 299.66. Gemcitbine
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More information27 June Bmnly L. WALTER ET AL.: RESPONSE OF CERVICAL CANCERS TO IRRADIATION
27 June 1964 Bmnly MEDICAL JOURNAL L. WALTER ET AL.: RESPONSE OF CERVICAL CANCERS TO IRRADIATION x 1,638.) FIG. 2.-Foci of sme tumour s in Fig. 1 contining vible tumour cells with scnty cytoplsm, reltively
More informationPROVEN ANTICOCCIDIAL IN NEW FORMULATION
PROVEN ANTICOCCIDIAL IN NEW FORMULATION Coxidin 100 microgrnulte A coccidiosttic dditive for roilers, chickens rered for lying nd turkeys Contins 100 g of monensin sodium per kg Aville s homogenous grnules
More informationcapacity in infants and children
Archives of Disese in Childhood, 1974, 49, 654. DDAVP test for estimtion of renl concentrting cpcity in infnts nd children A. S. ARONSON nd N. W. SVENNINGSEN From the Deprtment of Peditrics, University
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BASAGLAR sfely nd effectively. See full prescribing informtion for BASAGLAR BASAGLAR (insulin glrgine
More informationComparison of three simple methods for the
J. clin. Pth. (1967), 2, 5 Comprison of three simple methods for the ssessment of 'free' thyroid hormone T. M. D. GIMLETTE1 From the Rdio-Isotope Lbortory, St. Thoms's Hospitl, London SYNOPSIS A dilysis
More informationTrends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public
More informationOriginal Article. Breast Care 2016;11: DOI: /
Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest
More informationOptimizing Metam Sodium Fumigation in Fine-Textured Soils
Optimizing Metm Sodium Fumigtion in Fine-Textured Soils Neil C Gudmestd University Distinguished Professor & Endowed Chir of Potto Pthology Deprtment of Plnt Pthology North Dkot Stte University Erly Dying
More informationTrends in Mortality From COPD Among Adults in the United States
[ Originl Reserch COPD ] Trends in Mortlity From COPD Among Adults in the United Sttes Erl S. Ford, MD, MPH BACKGROUND: COPD imposes lrge public helth burden interntionlly nd in the United Sttes. The objective
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More information